Developer docs
API playgroundTry for free, no card

Search company profiles

Sun Yat-sen University Cancer Center

Full company profile

uuid00esd11

Namestring
Sun Yat-sen University Cancer Center
Websiteurl
https://english.sysucc.org.cn
Company typeenum
Private
Founded yearint
1964
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

No data
No data
Differentiator
Functional benefit
Problem solved
No data
Market position
Customer concentration

Classification, Details

No data
API detail

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sun Yat-sen University Cancer Center

english.sysucc.org.cn

Sun Yat-sen University Cancer Center firmographics

Firmographics
Name
Sun Yat-sen University Cancer Center
Website
https://english.sysucc.org.cn
Company type
Private
Founded year
1964
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Where Sun Yat-sen University Cancer Center is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Markets served

Sun Yat-sen University Cancer Center technology and API

Technology

API detail

API docs
API detail

Core technology

AI maturity

App detail

Sun Yat-sen University Cancer Center competitors and assessment

Company assessment

Market position

Customer concentration

Sun Yat-sen University Cancer Center social profiles

Digital presence

Sun Yat-sen University Cancer Center financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sun Yat-sen University Cancer Center leadership team

Management profile

Number of profiles

Sun Yat-sen University Cancer Center funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sun Yat-sen University Cancer Center M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sun Yat-sen University Cancer Center

When was Sun Yat-sen University Cancer Center founded?

Sun Yat-sen University Cancer Center was founded in 1964. It employs 1,001 to 5,000 people.

Where is Sun Yat-sen University Cancer Center based?

Sun Yat-sen University Cancer Center is headquartered in Guangzhou, China, in the Asia region.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioengineeringImmune-toxicity model and efficacy biomarkers enable precise NSCLCResearchers from Sun Yat-Sen University Cancer Center reported that a gene-expression signature linked to T helper 17 cell differentiation predicts severe immune-related adverse events in advanced non-small cell lung cancer patients treated with the anti-PD-1 antibody sintilimab plus chemotherapy. The model achieved an AUC of 0.904 in training and 0.769 in validation cohorts. Combined with PD-L1 and tumor-infiltrating lymphocyte markers, it stratified patients into four risk-benefit groups with response rates from 92.9 to 51.1 percent. External validation is needed before clinical use.BioWorldYM-1240 targets EZH2 and HDAC to suppress lymphomaResearchers from Sun Yat-sen University Cancer Center reported the preclinical characterization of YM-1240, a novel EZH2/HDAC dual inhibitor, in lymphoma models. The study was published in July 2026.WileyApplication of Artificial Intelligence Software to Identify Emotions of Lung Cancer Patients in Preoperative Health Education: A Cross-Sectional StudyA cross-sectional study at Sun Yat-sen University Cancer Center in China analyzed the impact of preoperative health education on the emotions of 210 lung cancer patients using FaceReader AI software. The research found that educational materials with an explanatory tone and negative sentiment significantly influenced patient emotional states, particularly increasing sadness and anger while decreasing fear. The findings suggest that refining the tone and emotional content of health education can improve the psychological well-being of lung cancer patients.National Center for Biotechnology InformationApplication of Artificial Intelligence Software to Identify Emotions of Lung Cancer Patients in Preoperative Health Education: A Cross‐Sectional StudyA cross-sectional study at Sun Yat-sen University Cancer Center in China analyzed 210 lung cancer patients to determine how preoperative health education tones affect their emotional states using AI-based emotion recognition software. The research found that educational materials with an explanatory tone and negative sentiment significantly impacted patient emotions, suggesting that refining communication styles can improve patient well-being.PR NewswireResults of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & OncologyQilu Pharmaceutical Co., Ltd. announced that the Phase I clinical trial results of its bifunctional antibody QL1706 were published in the Journal of Hematology & Oncology on May 8, 2023, with the study led by researchers at Sun Yat-sen University Cancer Center. The trial enrolled 518 patients and demonstrated that QL1706 was well tolerated with an objective response rate of 16.9% across advanced solid tumors, including higher responses in nasopharyngeal carcinoma (24.5%), cervical cancer (27.3%), and non-small cell lung cancer (14.0%). The drug has advanced into multiple Phase III clinical trials for cervical cancer, NSCLC adjuvant treatment, advanced NSCLC, and nasopharyngeal carcinoma.PR NewswireAntengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell LymphomaAntengene Corporation Limited has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) to conduct a Phase Ib dose-escalation study evaluating ATG-008 (onatasertib) in combination with ATG-010 (selinexor) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). The study will enroll patients at ten centers across China, with Sun Yat-Sen University Cancer Center serving as the primary trial site, aiming to determine the recommended dose and assess safety and efficacy of the combination regimen. ATG-010 (selinexor) is already FDA-approved as a single agent for this indication, while ATG-008 is a selective mTOR inhibitor that has demonstrated antitumor activity in preclinical DLBCL models.PR NewswireDelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate UpdatesDelMar Pharmaceuticals reported fiscal year 2019 financial results with a net loss of approximately $8.0 million, improved from $11.1 million the prior year, and announced it had sufficient capital to fund operations through the fourth quarter of 2020 following two financings totaling approximately $9.9 million. The company provided clinical trial updates on its VAL-083 Phase 2 studies for MGMT-unmethylated GBM patients being conducted at MD Anderson Cancer Center and Sun Yat-sen University Cancer Center in China, with interim results showing 16 of 17 assessed patients achieving either complete response or stable disease. DelMar also relocated its headquarters to San Diego, California in September 2019.PR NewswireDelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of CliniDelMar Pharmaceuticals presented clinical trial updates for VAL-083 in MGMT-unmethylated glioblastoma at the 2019 ASCO annual meeting. In the first-line Phase 1/2 trial at Sun Yat-sen University Cancer Center in China, 18 patients were enrolled with 53.3% achieving complete response and 46.7% stable disease as best response. The second-line Phase 2 trial at MD Anderson Cancer Center enrolled 51 patients, with stable disease observed in 25.7% of patients on the 40 mg/m2 dose and 33.3% on the 30 mg/m2 dose, comparing against a historical overall survival benchmark of 7.2 months with lomustine.